INTI
Inhibitor Therapeutics, Inc.Company with tickers: INTI
CIK
1042418
CUSIP
45720M105
Shares Outstanding
172,573,545
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $695,632 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $340,562 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-695,632 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-686,425 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |